And this from Nature (01 March 2017):
“Hepatitis C drugs re-energize global fight over patents
Lawsuits in India and Argentina seek to reduce drug costs by allowing generic versions of antiviral treatments.”
http://www.nature.com/news/hepatitis-c-drugs-re-energize-global-fight-over-patents-1.21558
The related story on “America’s Drug Problem” (Nature Biotechnology, 14 November 2016) is also worth looking at:
http://www.nature.com/nbt/journal/v34/n12/full/nbt.3734.html
Well, it’s good to see that price-gouging by big pharma is becoming a serious subject in some top scientific journals…
Diagnosed Jan 2015: GT3, A0+F0/F1. Fatigue + Brain-Fog.
Started Sof+Dac from fixHepC 10-Nov-2015. NO sides.
Pre-Tx: AST 82, ALT 133, Viral Load 1 900 000.
Week4: AST 47, ALT 58. VL < 15 (unquantifiable).
Week12 (EOT): AST 30, ALT 26, VL UND
Week16 (EOT+4): AST 32, ALT 28, GGT 24, VL UND
Week28 (EOT+16): AST 26, ALT 22, GGT 24, VL UND
Ever grateful to Dr James.
Relapsed somewhere after all that... Bummer!
Jan 2018: VL 63 000 (still GT3).
.
